August 2019

Call for translational and preclinical research Letter of Intent proposals in the area of osteosarcoma metastasis

Background

TThe Osteosarcoma Institute (OSI) was established in November 2017 to develop a comprehensive, rational strategy that will lead to a major improvement in the life expectancy of osteosarcoma patients, particularly those with relapsed and metastatic disease. As part of a comprehensive approach to improve outcomes for osteosarcoma patients OSI hereby seeks to support translational and preclinical research proposals in the area of osteosarcoma metastasis.

Contemporaneously, OSI has announced a call for Letter of Intent proposals to support a clinical study to test the activity of a novel therapeutic approach in recurrent/metastatic osteosarcoma.

Application guidance

Applications must be submitted through Proposal Central.  Applicants should visit https://proposalcentral.com, create an account, if necessary, and login.  Then, select the Grant Opportunities tab and enter “Osteosarcoma Institute” in the search box. The application is available by clicking Apply Now on the Translational and Preclinical Study line.

This translational and preclinical science RFP seeks to support the development of a novel therapeutic approach that targets pulmonary metastatic osteosarcoma lesions or the process of pulmonary metastatic progression.

The features of an optimal preclinical dataset for osteosarcoma metastasis drug development have been reported (Khanna et al, Clin Can Res 2014). Briefly, an ideal dataset would have the following features:

  • a drug target demonstrated to be relevant in osteosarcoma metastasis, rigorously and mechanistically tested in multiple preclinical models across preclinical model species, and in human osteosarcoma metastatic cells and/or lesions;
  • the availability of a therapeutic candidate or drug suitable for preclinical studies; a testable PD marker of effective drug exposure;
  • a correlative biomarker that may be translated to human patients in support of optimal dosing.

Applicants are encouraged to describe how their proposal will contribute to the establishment of such a dataset, either by addressing existing gaps or otherwise.

Funding will include up to $250,000 per year, not to exceed a total of $500,000. Funding can be used to support any aspect of the preclinical and translational path, with indirect costs not to exceed 10%.

A cover letter is not required but may be added as an attachment to the application.

Timeline:

  • Letter of Intent proposals due October 15, 2019
  • Reviews will be completed by January 15, 2020
    Requests for full proposals will be made immediately after reviews are completed
  • Full protocol submission due by April 15, 2020
  • Award and funding by June 1, 2020

Published by the Osteosarcoma Institute on September 5, 2019.